Skip to main content

Biogen Inc.

BIIB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000875045

In the last 90 days, Biogen Inc. insiders filed 0 open-market purchases and 1 sale; 1,046 institutions reported holding it in 13F filings for Q2 2026, worth $33.2B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Biogen Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $239.7K in total
Insiders trading
1
Net value
−$239.7K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Biogen Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Biogen Inc.
NameTitleLast reported holdingLast filingFilings, past year
Parini MichaelChief Legal Officer–Sep 3, 20261
Minor LloydDirector2,689Aug 5, 20262
Sherwin Stephen ADirector15,193Jun 11, 20261
Hawkins William ADirector10,365Jun 11, 20261
Rowinsky Eric KDirector25,844Jun 11, 20261
Freire Maria CDirector8,820Jun 11, 20261
Mantas Jesus BDirector11,263Jun 11, 20261
Patolawala Monish DDirector5,215Jun 11, 20261
Langer SusanDirector6,634Jun 11, 20261
Pangalos Menelas NDirector3,875Jun 11, 20261
Keeney AdamHead of Corporate Development6,365May 5, 20263
Godbout SeanChief Accounting Officer1,342Apr 3, 20264
Alexander Susan HEVP Chief Legal Officer41,807Feb 17, 20262
Gregory GingerEVP, Human Resources22,359Feb 17, 20262
Kramer RobinChief Financial Officer11,472Feb 17, 20262
Singhal PriyaHead of Development8,043Feb 17, 20263
Viehbacher ChristopherPresident and CEO29,924Feb 17, 20263
Izzar RachidHead of Global Product Strat.11,011Feb 17, 20262
Murphy NicoleHead of Pharm Ops and Tech19,611Feb 17, 20262
Grogan JaneHead of Research4,058Feb 17, 20263
Dorsa CarolineDirector31,002Jun 18, 20250
McDonnell Michael REVP, Chief Financial Officer24,341Feb 12, 20250
Papadopoulos SteliosDirector10,095Jun 17, 20220
Jones William DDirector2,145Jun 17, 20220
Denner Alexander JDirector15,099Jun 17, 20220
Mulligan RichardDirector15,099Jun 17, 20220
Vounatsos MichelChief Executive Officer67,261Feb 23, 20220
Guindo ChirfiHead of Glob Prod Strat & Com7,364Feb 23, 20220
Galdes AlphonseEVP Pharmaceutical Oper & Tech5,064Jan 21, 20220
Leaming NancyDirector13,763Jul 2, 20210
Posner Brian SDirector8,175Jul 2, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 5, 2026 (view filing)4:03 PM ETAug 3-42 daysMinor LloydDirectorSSale−1.19K$202.15−$239.7K−30.6%2.69K after2 lots10b5-1
Feb 17, 2026 (view filing)Feb 125 daysMurphy NicoleHead of Pharm Ops and TechPPurchase+3$195.04+$585.120.0%19.6K after
Feb 10, 2026 (view filing)Feb 91 daySinghal PriyaHead of DevelopmentSSale−2.66K$199.83−$531.5K−24.9%8.04K after10b5-1
Feb 3, 2026 (view filing)Feb 21 daySinghal PriyaHead of DevelopmentSSale−748$179.30−$134.1K−10.7%6.27K after10b5-1
Sep 2, 2025 (view filing)Sep 2Same daySinghal PriyaHead of DevelopmentSSale−517$133.55−$69.0K−8.2%5.77K after10b5-1
Jul 16, 2025 (view filing)Jul 88 daysLateIzzar RachidHead of Global Product Strat.SSale−2.22K$135.00−$300.1K−26.0%6.33K after10b5-1
May 20, 2025 (view filing)May 191 daySinghal PriyaHead of DevelopmentSSale−3.81K$126.25−$480.5K−41.2%5.43K after10b5-1
May 5, 2025 (view filing)May 23 daysDorsa CarolineDirectorPPurchase+1.24K$122.72+$151.6K+4.6%27.8K after
Mar 10, 2025 (view filing)Mar 73 daysSherwin Stephen ADirectorSSale−8.76K$150.02−$1.31M−43.6%11.3K after10b5-1
Dec 9, 2024 (view filing)Dec 9Same daySinghal PriyaHead of DevelopmentSSale−110$157.21−$17.3K−2.0%5.43K after10b5-1
Sep 5, 2024 (view filing)Sep 32 daysSinghal PriyaHead of DevelopmentSSale−431$204.22−$88.0K−7.5%5.32K after10b5-1
Apr 3, 2024 (view filing)Apr 21 daySinghal PriyaHead of DevelopmentSSale−93$213.09−$19.8K−1.9%4.89K after10b5-1
Feb 26, 2024 (view filing)Feb 224 daysSinghal PriyaHead of DevelopmentSSale−262$221.23−$58.0K−5.1%4.89K after10b5-1
Feb 21, 2024 (view filing)Feb 165 daysSinghal PriyaHead of DevelopmentSSale−108$221.49−$23.9K−2.1%5.15K after10b5-1
Feb 20, 2024 (view filing)Feb 155 daysRowinsky Eric KDirectorPPurchase+455$222.54+$101.3K+2.3%20.6K after
Feb 13, 2024 (view filing)Feb 121 daySinghal PriyaHead of DevelopmentSSale−419$239.45−$100.3K−8.5%4.52K after10b5-1
Feb 5, 2024 (view filing)Feb 23 daysSinghal PriyaHead of DevelopmentSSale−634$245.93−$155.9K−13.4%4.10K after10b5-1
Dec 12, 2023 (view filing)Dec 111 daySinghal PriyaHead of DevelopmentSSale−110$248.00−$27.3K−3.1%3.46K after10b5-1
Sep 6, 2023 (view filing)Sep 51 daySinghal PriyaHead of DevelopmentSSale−431$269.43−$116.1K−11.4%3.35K after10b5-1
Jul 5, 2023 (view filing)Jul 32 daysSinghal PriyaHead of DevelopmentSSale−81$282.87−$22.9K−2.7%2.92K after10b5-1
May 2, 2023 (view filing)Apr 284 daysGregory GingerEVP, Human ResourcesSSale−2.68K$300.00−$804.3K−24.0%8.48K after10b5-1
Apr 6, 2023 (view filing)Apr 42 daysSinghal PriyaHead of DevelopmentSSale−91$277.11−$25.2K−3.1%2.84K after10b5-1
Mar 30, 2023 (view filing)Mar 282 daysSinghal PriyaHead of DevelopmentSSale−568$270.06−$153.4K−16.7%2.84K after
Dec 12, 2022 (view filing)Nov 1428 daysLateGregory GingerEVP, Human ResourcesSSale−5.61K$300.11−$1.68M−49.6%5.71K after
Oct 28, 2022 (view filing)Oct 271 dayAlexander Susan HEVP Chief Legal Off & Corp SecSSale−5.53K$280.70−$1.55M−12.3%39.4K after